John R. Graybill

19.7k citations

257 papers · 14.4k indexed · 3 hit papers · h-index 60

Impact in

Infectious Diseases top 0.02%
- Antifungal resistance and susceptibility
Epidemiology top 0.05%
- Fungal Infections and Studies
- Nail Diseases and Treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Cytomegalovirus and herpesvirus research

Papers in

Infectious Diseases 194
- Antifungal resistance and susceptibility 184
Small Animals 45
- Infectious Diseases and Mycology 39

Co-authors: Laura K. Najvar Michael G. Rinaldi William E. Dismukes Rosie Bocanegra Jack D. Sobel Richard J. Hamill William G. Powderly David A. Stevens
Journals: Antimicrobial Agents and Chemotherapy (69 papers)Clinical Infectious Diseases (23 papers)Medical Mycology (20 papers)Journal of Antimicrobial Chemotherapy (12 papers)The American Journal of Medicine (11 papers)
Partner nations: United States Mexico United Kingdom

In The Last Decade

John R. Graybill

255 papers receiving 13.5k citations

Hit Papers

align trajectories log scale

Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America 2010 · 1.7k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2010 Clinical Infectious Diseases
2000 Medicine
1997 New England Journal of Medicine

Peers

Countries citing papers authored by John R. Graybill

Since Specialization

Citations

This map shows the geographic impact of John R. Graybill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John R. Graybill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John R. Graybill more than expected).

Fields of papers citing papers by John R. Graybill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John R. Graybill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John R. Graybill. The network helps show where John R. Graybill may publish in the future.

Co-authors

The 25 scholars most cited alongside John R. Graybill, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John R. Graybill Line = papers co-authored together John R. Graybill links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Ketoconazole Therapy for Systemic Fungal Infections American Review of Respiratory Disease ·John R. Graybill, Philip C. Craven, William H. Donovan, Angelo Brás Fernandes Callau	2015	0
2	Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America Clinical Infectious Diseases ·John R. Perfect, William E. Dismukes, Françoise Dromer, David L. Goldman, John R. Graybill, Richard J. Hamill, Thomas S. Harrison, Robert A. Larsen, Olivier Lortholary, H. Spängler, Peter G. Pappas, William G. Powderly, Nina Singh, Jack D. Sobel, Tania C. Sorrell Hit paper breakdown →	2010	1749
3	Comparison of 2 Doses of Liposomal Amphotericin B and Conventional Amphotericin B Deoxycholate for Treatment of AIDS‐Associated Acute Cryptococcal Meningitis: A Randomized, Double‐Blind Clinical Trial of Efficacy and Safety Clinical Infectious Diseases ·Richard J. Hamill, Jack D. Sobel, Wafaa El‐Sadr, Philip C. Johnson, John R. Graybill, Michael Fountoulakisc, David E. Barker	2010	120
4	In Vivo Efficacy of Anidulafungin and Caspofungin against Candida glabrata and Association with In Vitro Potency in the Presence of Sera Antimicrobial Agents and Chemotherapy ·Nathan P. Wiederhold, Laura K. Najvar, Rosie Bocanegra, D. Kimberley Molina, Marcos Olivo, John R. Graybill	2007	64
5	Antimicrobial Resistance Prevention Initiative—An Update: Proceedings of an Expert Panel on Resistance The American Journal of Medicine ·Robert C. Moellering, John R. Graybill, John E. McGowan, Lawrence Corey	2007	58
6	Disruption of a Nonribosomal Peptide Synthetase in Aspergillus fumigatus Eliminates Gliotoxin Production Eukaryotic Cell ·Robert A. Cramer, Michael P. Gamcsik, I. V. Petrov, Laura K. Najvar, William R. Kirkpatrick, Thomas F. Patterson, Carl J. Balibar, John R. Graybill, John R. Perfect, Soman N. Abraham, William J. Steinbach	2006	168
7	Retinal Function Assessed by ERG Before and After Induction of Ocular Aspergillosis and Treatment by the Anti-fungal, Micafungin, in Rabbits Documenta Ophthalmologica ·Joseph M. Harrison, Randolph D. Glickman, Wenyu Jiang, Y. Trigo, ahmad aris fajaruddin, 香月尚子, Laura K. Najvar, Zhendong Song, Tomo Anadolac, William Eric Sponsel, John R. Graybill, William C. Lloyd, Margaret Miller, E. E. Bradford, Marc Provoost, Aaron M. Miller, 立敏史	2005	14
8	Micafungin vs Amphotericin B in the Treatment of Experimental Aspergillosis Endophthalmitis Investigative Ophthalmology & Visual Science ·E. E. Bradford, Marc Provoost, Zhen Shan Gao, Y. Trigo, Alberta Marx, Laura K. Najvar, Randolph D. Glickman, Jay M. Harrison, John R. Graybill, William Eric Sponsel	2004	3
9	Experimental murine model of disseminatedPseudallescheriainfection Medical Mycology ·Gloria M. González, Rolando Tijerina, Laura K. Najvar, Michael G. Rinaldi, I‐Tien Yeh, John R. Graybill	2002	17
10	Disseminated Mycobacterium simiae Infection in Patients with AIDS Journal of Infection ·Hail M. Al-Abdely, Sanjay G. Revankar, John R. Graybill	2000	39
11	SCH56592 treatment of murine invasive aspergillosis Antimicrobial Agents and Chemotherapy ·John R. Graybill	1998	1
12	SCH56592 treatment of murine invasive aspergillosis Journal of Antimicrobial Chemotherapy ·John R. Graybill, Rosie Bocanegra, Laura K. Najvar, Michael Luther, David Loebenberg	1998	45
13	Discrepancy between in vitro and in vivo antifungal activity of albendazole. PubMed ·T C Hardin, Laura K. Najvar, Jinee Rizzo, Annette W. Fothergill, Michael G. Rinaldi, John R. Graybill	1997	7
14	ZD0870 treatment of murine candidiasis caused by fluconazole resistant isolates of Candida albicans Journal of Antimicrobial Chemotherapy ·Laura K. Najvar, Rune Godøy Statoil, David Burr Ujljl, Michael Luther, John R. Graybill	1996	4
15	Clinical Isolates of Mycobacterium Simiae in San Antonio, Texas. An 11-Yr Review American Journal of Respiratory and Critical Care Medicine ·W.-U. Mutert, Jay I. Peters, J H Jorgensen, John R. Graybill	1995	51
16	Treatment of coccidioidomycosis with SCH 39304 Medical Mycology ·J.S. Hostetler, Antonino Catanzaro, David A. Stevens, John R. Graybill, P. K. Sharkey, Robert A. Larsen, Richard Tucker, P. Marcinowski, Michael G. Rinaldi, Gretchen A. Cloud, J N Galgiani	1994	10
17	Treatment of sporotrichosis with itraconazole The American Journal of Medicine ·Patricia D. Mills, Carol A. Kauffman, John R. Graybill, David A. Stevens, Sara Rothlin, Gretchen Cloud, William E. Dismukes	1993	108
18	Chemotherapy of the pulmonary mycoses American Review of Respiratory Disease ·George A. Sarosi, Joseph H. Bates, Robert W. Bradsher, Lin-Hau Lee, William E. Dismukes, 张信民, John R. Graybill, John P. Utz	1988	2
19	Proceedings of a symposium on new developments in therapy for the mycoses. The American Journal of Medicine ·John R. Graybill	1983	5
20	[Immunotherapy of coccidiomycosis]. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·John R. Graybill	1976	4

About John R. Graybill

John R. Graybill is a scholar working on Infectious Diseases, Small Animals, Epidemiology, Microbiology and Microbiology, having authored 257 papers that have together received 14.4k indexed citations. Recurring topics across this work include Antifungal resistance and susceptibility (184 papers), Fungal Infections and Studies (169 papers), Nail Diseases and Treatments (84 papers), Infectious Diseases and Mycology (39 papers), Pneumocystis jirovecii pneumonia detection and treatment (18 papers), Plant Pathogens and Fungal Diseases (16 papers), Toxin Mechanisms and Immunotoxins (13 papers) and Antimicrobial Peptides and Activities (9 papers). The work is most often cited by research in Infectious Diseases (10.9k citations), Epidemiology (10.7k citations), Microbiology (197 citations), Small Animals (1.7k citations) and Microbiology (538 citations). John R. Graybill has collaborated with scholars based in United States, Mexico and United Kingdom. Frequent co-authors include Laura K. Najvar, Michael G. Rinaldi, William E. Dismukes, Rosie Bocanegra, Jack D. Sobel, Richard J. Hamill, William G. Powderly, David A. Stevens, Thomas F. Patterson and Peter G. Pappas. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Clinical Infectious Diseases, Medical Mycology, Journal of Antimicrobial Chemotherapy and The American Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact